Key clinical point: One of the key factors influencing contraceptive use in premenopausal women with early breast cancer (BC) is the use of contraception at the time of diagnosis.
Major finding: At diagnosis, 54.2% of patients reported using contraceptives, mostly hormonal (62.7%); however, the use of contraception decreased significantly to 38.9% and 41.2% at the first and second year, respectively ( P < .001). The use of contraception at diagnosis was associated with higher odds of contraceptive use at years 1 (adjusted odds ratio [aOR] 4.02; 95% CI 3.15-5.14) and 2 (aOR 3.12; 95% CI 2.36-4.14) after diagnosis.
Study details : Findings are from an analysis of the prospective, Cancer Toxicity (CANTO) study including 2900 premenopausal women with early BC.
Disclosures: The CANTO study is supported by the Investment for the Future program of the National Research Agency of France. The authors declared serving as advisors, owning stocks, or receiving grants, personal fees, or royalties from several sources.
Source: Lambertini M et al. Contraceptive use in premenopausal women with early breast cancer. JAMA Netw Open. 2022;5(9):e2233137 (Sep 23). Doi: 10.1001/jamanetworkopen.2022.33137